Gao Zhiyuan, Mao Yajie, Sun Yichen, Tong Liping, Liu Honggang, Wang Tianhu, Shao Changjian, Duan Hongtao, Yan Xiaolong
Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Department of Thoracic Surgery, Third Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Thorac Cancer. 2025 Aug;16(16):e70149. doi: 10.1111/1759-7714.70149.
Lung cancer is a leading cause of cancer-related deaths. Perioperative therapies, including neoadjuvant chemo-immunotherapy, have improved outcomes, but combining them with antiangiogenic drugs may offer further benefits. This study evaluated the 3-year efficacy and safety of neoadjuvant sintilimab, anlotinib, and chemotherapy in resectable NSCLC patients from the TD-NeoFOUR trial.
The study included 45 patients who received neoadjuvant treatment with anlotinib, sintilimab, and platinum-based chemotherapy. The primary endpoint was overall survival (OS), and the secondary endpoint was event-free survival (EFS). The Kaplan-Meier method was used to estimate survival curves, and the log-rank test was used to compare survival rates between subgroups.
As of November 11, 2024, all 45 patients had been followed up for a median of 35.7 months. The estimated 3-year EFS rate was 84.3%, and the estimated 3-year OS rate was 86.7%. Subgroup analysis showed that patients achieving pathological complete response (pCR) and major pathological response (MPR) had significantly higher 3-year EFS and OS rates compared to patients with non-pCR and non-MPR. No new treatment-related adverse events (TRAEs) occurred during the 3-year follow-up, indicating the long-term safety of the treatment regimen.
The combination of neoadjuvant chemo-immunotherapy and antiangiogenic drugs significantly improved long-term survival outcomes in patients with resectable NSCLC. This treatment regimen is a promising option for improving prognosis in this patient population.
肺癌是癌症相关死亡的主要原因。围手术期治疗，包括新辅助化疗免疫疗法，已改善了治疗结果，但将它们与抗血管生成药物联合使用可能会带来更多益处。本研究评估了替雷利珠单抗、安罗替尼和化疗新辅助治疗在可切除非小细胞肺癌（NSCLC）患者中的3年疗效和安全性，该研究来自TD-NeoFOUR试验。
该研究纳入了45例接受安罗替尼、替雷利珠单抗和铂类化疗新辅助治疗的患者。主要终点是总生存期（OS），次要终点是无事件生存期（EFS）。采用Kaplan-Meier方法估计生存曲线，采用对数秩检验比较亚组间的生存率。
截至2024年11月11日，所有45例患者的中位随访时间为35.7个月。估计的3年EFS率为84.3%，估计的3年OS率为86.7%。亚组分析显示，与未达到病理完全缓解（pCR）和主要病理缓解（MPR）的患者相比，达到pCR和MPR的患者的3年EFS和OS率显著更高。在3年随访期间未发生新的治疗相关不良事件（TRAEs），表明该治疗方案具有长期安全性。
新辅助化疗免疫疗法与抗血管生成药物联合使用可显著改善可切除NSCLC患者的长期生存结果。该治疗方案是改善该患者群体预后的一个有前景的选择。
